Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors.
A series of diaryl ureas with an amide substitution at the 4-position was prepared and found to be potent and selective FLT3 inhibitors with good oral bioavailability and efficacy in a tumor xenograft model.
Patel
Hitesh K
HK
Ambit Biosciences Inc., 4215 Sorrento Valley Boulevard, San Diego, CA 92121, USA.
Grotzfeld
Robert M
RM
Lai
Andiliy G
AG
Mehta
Shamal A
SA
Milanov
Zdravko V
ZV
Chao
Qi
Q
Sprankle
Kelly G
KG
Carter
Todd A
TA
Velasco
Anne Marie
AM
Fabian
Miles A
MA
James
Joyce
J
Treiber
Daniel K
DK
Lockhart
David J
DJ
Zarrinkar
Patrick P
PP
Bhagwat
Shripad S
SS
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D045744:Cell Line, Tumor; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D013329:Structure-Activity Relationship; D014508:Urea / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000493:pharmacokinetics; D023041:Xenograft Model Antitumor Assays; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000970:Antineoplastic Agents; D014508:Urea; D051941:fms-Like Tyrosine Kinase 3